Clinical Trials and Expanded Access Policy

ImmPACT Bio is committed to providing transformative therapies to patients who have exhausted available treatment options. At this early stage of development, ImmPACT Bio is not providing expanded access to our investigational CAR T cell therapies. As clinical experience with these products progresses, we plan to revisit this policy and will make updates as needed. If you are a patient or physician interested in accessing our investigational therapies, please visit www.clinicaltrials.gov and search for ImmPACT Bio to learn more about our ongoing clinical trials or click here:

Study Details | Study of IMPT-314 in R/R Aggressive B-cell | ClinicalTrials.gov

Study Details | Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE) | ClinicalTrials.gov

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.